Network Pharmacology, Molecular Docking and Experimental Verification Revealing the Mechanism of Fule Cream against Childhood Atopic Dermatitis

Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..

BACKGROUND: The Fule Cream (FLC) is an herbal formula widely used for the treatment of pediatric atopic dermatitis (AD), however, the main active components and functional mechanisms of FLC remain unclear. This study performed an initial exploration of the potential acting mechanisms of FLC in childhood AD treatment through analyses of an AD mouse model using network pharmacology, molecular docking technology, and RNA-seq analysis.

METHODS: The main bioactive ingredients and potential targets of FLC were collected from the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) and SwissTargetPrediction databases. An herb-compound-target network was built using Cytoscape 3.7.2. The disease targets of pediatric AD were searched in the DisGeNET, Therapeutic Target Database (TTD), OMIM, DrugBank and GeneCards databases. The overlapping targets between the active compounds and the disease were imported into the STRING database for the construction of the protein-protein interaction (PPI) network. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of the intersection targets were performed, and molecular docking verification of the core compounds and targets was then performed using AutoDock Vina 1.1.2. The AD mouse model for experimental verification was induced by MC903.

RESULTS: The herb-compound-target network included 415 nodes and 1990 edges. Quercetin, luteolin, beta-sitosterol, wogonin, ursolic acid, apigenin, stigmasterol, kaempferol, sitogluside and myricetin were key nodes. The targets with higher degree values were IL-4, IL-10, IL-1α, IL-1β, TNFα, CXCL8, CCL2, CXCL10, CSF2, and IL-6. GO enrichment and KEGG analyses illustrated that important biological functions involved response to extracellular stimulus, regulation of cell adhesion and migration, inflammatory response, cellular response to cytokine stimulus, and cytokine receptor binding. The signaling pathways in the FLC treatment of pediatric AD mainly involve the PI3K-Akt signaling pathway, cytokine‒cytokine receptor interaction, chemokine signaling pathway, TNF signaling pathway, and NF-κB signaling pathway. The binding energy scores of the compounds and targets indicate a good binding activity. Luteolin, quercetin, and kaempferol showed a strong binding activity with TNFα and IL-4.

CONCLUSION: This study illustrates the main bioactive components and potential mechanisms of FLC in the treatment of childhood AD, and provides a basis and reference for subsequent exploration.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - year:2023

Enthalten in:

Current computer-aided drug design - (2023) vom: 02. Okt.

Sprache:

Englisch

Beteiligte Personen:

Liu, Chang [VerfasserIn]
Liu, Yuxin [VerfasserIn]
Liu, Yi [VerfasserIn]
Guan, Jing [VerfasserIn]
Gao, Ying [VerfasserIn]
Ou, Ling [VerfasserIn]
Qi, Yuenan [VerfasserIn]
Lv, Xiaoxi [VerfasserIn]
Zhang, Jianmin [VerfasserIn]

Links:

Volltext

Themen:

AD mice model
Childhood atopic dermatitis
Fule Cream
Journal Article
Molecular docking
Network pharmacology

Anmerkungen:

Date Revised 09.10.2023

published: Print-Electronic

Citation Status Publisher

doi:

10.2174/0115734099257922230925074407

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM363007628